Results 71 to 80 of about 18,376 (235)
Malaria Journal, 2019 Background To reduce onward falciparum malaria transmission, the World Health Organization recommends adding single low-dose (SLD) primaquine to artemisinin-based combination treatment in low transmission areas. However, uptake of this recommendation has
Jaishree Raman +8 more
doaj +1 more source
Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children [PDF]
, 2017 Low-dose primaquine is recommended to prevent Plasmodium falciparum malaria transmission in areas threatened by artemisinin resistance and areas aiming for malaria elimination.
Bousema, Teun +8 more
core +2 more sources
Journal of Infection in Developing Countries, 2023 Hyperparasitaemia is an important event in the cascade of Plasmodium falciparum severe malaria (SM), and may also lead to SM associated complications and death, if left untreated.
Benudhar Mukhi +5 more
doaj +1 more source
Archiv der Pharmazie, Volume 359, Issue 1, January 2026.Novel nitro‐substituted diaryl 1,3,4‐ and 1,2,4‐oxadiazoles were synthesised via molecular hybridisation of bioactive heterocycles. Selected derivatives exhibited potent antimicrobial activity, including against Mycobacterium tuberculosis and Staphylococcus aureus, and cholinesterase inhibitory activity, with promising selectivity.
Enikő Šikorová +9 more
wiley +1 more source
The reality of using primaquine
Malaria Journal, 2010 Background Primaquine is currently the only medication used for radical cure of Plasmodium vivax infection. Unfortunately, its use is not without risk. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased susceptibility to ...
Bancone Germana +2 more
doaj +1 more source
Reactivity of Blood Samples Spotted onto Filter Papers in the WST-8 Method for Screening of G6PD Deficiency. [PDF]
, 2006 Deficiency of glucose-6-phosphate dehydrogenase (G6PD) causes acute hemolytic anemia triggered by oxidative drugs such as primaquine. It is therefore essential in malaria-endemic areas for malaria patients to be confirmed for their G6PD activity before ...
Arai, Meiji +3 more
core +1 more source
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels
British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 109-118, January 2026.This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Guilherme Suarez‐Kurtz
wiley +1 more source
Factors affecting primaquine combination treatment in Malaria patients in Selangor, Malaysia
Journal of Pharmacy and Bioallied Sciences, 2017 Introduction: Primaquine is vital for the management of liver-stage Plasmodium vivax and Plasmodium ovale malaria. However, primaquine effectiveness is dependent on various factors and differs between populations.
Norliza Mat Ariffin +4 more
openalex +3 more sources
Molecular Genetics &Genomic Medicine, Volume 14, Issue 1, January 2026.This study evaluated pharmacogenomic (PGx) calling from whole‐exome sequencing (WES) in 3562 Taiwanese individuals. Fourteen pharmacogenes were reliably identified, with each person carrying an average of ~2.4 actionable phenotypes. The high actionable frequencies of G6PD deficiency and HLA‐B*58:01 highlight ethnic differences and support WES as a ...
Hsu‐Heng Lin +9 more
wiley +1 more source
Tropical Medicine and Health, 2018 Background Alongside monitoring of the disease burden, the successful move towards malaria elimination relies on the readiness of the health care delivery system.
Kay Thwe Han +7 more
doaj +1 more source